Abstract
1534P First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have